Bone marrow-derived mesenchymal stem cells ameliorate autoimmune enteropathy independently of regulatory T cells - PubMed (original) (raw)
Bone marrow-derived mesenchymal stem cells ameliorate autoimmune enteropathy independently of regulatory T cells
Biju Parekkadan et al. Stem Cells. 2008 Jul.
Abstract
Cell-based tolerogenic therapy is a relatively new approach for the treatment of autoimmune diseases. Mesenchymal stem cells (MSCs) have been shown to be potent immunomodulatory agents in a number of experimental and clinical scenarios; however, their use in various autoimmune diseases is undefined. Herein, we report the efficacy of MSC transplantation in a multiorgan autoimmunity model. Mice with defective peripheral tolerance caused by a deficiency in regulatory T cells were used as a testbed for therapy. After screening multiple target tissues of autoimmune attack, we observed an MSC-specific improvement in the histopathology of the distal ileum of treated mice. We then showed that MSCs can reduce mesenteric lymph node (MLN) cellularity in autoimmune mice during active disease and decrease activated T-cell populations in the MLN. Trafficking studies using enhanced green fluorescent protein (eGFP)-reporter MSCs revealed no appreciable engraftment in the intestine, but it did reveal the presence of eGFP+ cells organized in clusters within the MLN, as well as ancillary nodes. Semiquantitative analysis showed no difference in the number of clusters; however, eGFP+ cells in MLNs compared with ancillary nodes had distinct fibroblastoid morphology and formed a network with neighboring eGFP+ cells. Finally, we show evidence that transplantation of MSCs caused global immunosuppression, as measured by increased CD4+ CD8+ thymocyte production and serum interleukin-10 and decreased serum interferon-gamma. These data implicate the intestine as a new site of MSC tolerance induction and should motivate additional studies evaluating the use of MSCs as a treatment for autoimmune enteropathies.
Similar articles
- Adipose-derived mesenchymal stem cells alleviate experimental colitis by inhibiting inflammatory and autoimmune responses.
González MA, Gonzalez-Rey E, Rico L, Büscher D, Delgado M. González MA, et al. Gastroenterology. 2009 Mar;136(3):978-89. doi: 10.1053/j.gastro.2008.11.041. Epub 2008 Nov 27. Gastroenterology. 2009. PMID: 19135996 - Treatment of experimental arthritis by inducing immune tolerance with human adipose-derived mesenchymal stem cells.
González MA, Gonzalez-Rey E, Rico L, Büscher D, Delgado M. González MA, et al. Arthritis Rheum. 2009 Apr;60(4):1006-19. doi: 10.1002/art.24405. Arthritis Rheum. 2009. PMID: 19333946 - Overexpression of CNTF in Mesenchymal Stem Cells reduces demyelination and induces clinical recovery in experimental autoimmune encephalomyelitis mice.
Lu Z, Hu X, Zhu C, Wang D, Zheng X, Liu Q. Lu Z, et al. J Neuroimmunol. 2009 Jan 3;206(1-2):58-69. doi: 10.1016/j.jneuroim.2008.10.014. Epub 2008 Dec 9. J Neuroimmunol. 2009. PMID: 19081144 - Mesenchymal stem cells can affect solid organ allograft survival.
Popp FC, Eggenhofer E, Renner P, Geissler EK, Piso P, Schlitt HJ, Dahlke MH. Popp FC, et al. Transplantation. 2009 May 15;87(9 Suppl):S57-62. doi: 10.1097/TP.0b013e3181a288aa. Transplantation. 2009. PMID: 19424009 Review. - Immunomodulation by mesenchymal stem cells and clinical experience.
Le Blanc K, Ringdén O. Le Blanc K, et al. J Intern Med. 2007 Nov;262(5):509-25. doi: 10.1111/j.1365-2796.2007.01844.x. J Intern Med. 2007. PMID: 17949362 Review.
Cited by
- Toward personalized cell therapies by using stem cells: seven relevant topics for safety and success in stem cell therapy.
de Sá Silva F, Almeida PN, Rettore JV, Maranduba CP, de Souza CM, de Souza GT, Zanette Rde S, Miyagi SP, Santos Mde O, Marques MM, Maranduba CM. de Sá Silva F, et al. J Biomed Biotechnol. 2012;2012:758102. doi: 10.1155/2012/758102. Epub 2012 Nov 20. J Biomed Biotechnol. 2012. PMID: 23226945 Free PMC article. Review. - Serum-starved adipose-derived stromal cells ameliorate crescentic GN by promoting immunoregulatory macrophages.
Furuhashi K, Tsuboi N, Shimizu A, Katsuno T, Kim H, Saka Y, Ozaki T, Sado Y, Imai E, Matsuo S, Maruyama S. Furuhashi K, et al. J Am Soc Nephrol. 2013 Mar;24(4):587-603. doi: 10.1681/ASN.2012030264. Epub 2013 Mar 7. J Am Soc Nephrol. 2013. PMID: 23471196 Free PMC article. - Induction of CD4+CD25+FOXP3+ regulatory T cells by mesenchymal stem cells is associated with modulation of ubiquitination factors and TSDR demethylation.
Khosravi M, Bidmeshkipour A, Cohen JL, Moravej A, Hojjat-Assari S, Naserian S, Karimi MH. Khosravi M, et al. Stem Cell Res Ther. 2018 Oct 25;9(1):273. doi: 10.1186/s13287-018-0991-1. Stem Cell Res Ther. 2018. PMID: 30359308 Free PMC article. - Immunoregulatory effect of mesenchymal stem cell via mitochondria signaling pathways in allergic asthma.
Huang M, Mehrabi Nasab E, Athari SS. Huang M, et al. Saudi J Biol Sci. 2021 Dec;28(12):6957-6962. doi: 10.1016/j.sjbs.2021.07.071. Epub 2021 Aug 2. Saudi J Biol Sci. 2021. PMID: 34866995 Free PMC article. - Mesenchymal stem cells inhibit multiple myeloma cells via the Fas/Fas ligand pathway.
Atsuta I, Liu S, Miura Y, Akiyama K, Chen C, An Y, Shi S, Chen FM. Atsuta I, et al. Stem Cell Res Ther. 2013;4(5):111. doi: 10.1186/scrt322. Stem Cell Res Ther. 2013. PMID: 24025590 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials